C-338A polymorphism of the endothelin-converting enzyme (ECE-1) gene and the susceptibility to sporadic late-onset Alzheimer’s disease and coronary artery disease

Renato Scacchi\textsuperscript{a,*}, Giuseppe Gambina\textsuperscript{b}, Elisabetta Broggio\textsuperscript{b}, Maria Ruggeri\textsuperscript{c} and Rosa Maria Corbo\textsuperscript{a,d}

\textsuperscript{a}CNR Institute of Molecular Biology and Pathology, c/o Department of Genetics and Molecular Biology, University “La Sapienza”, Rome, Italy
\textsuperscript{b}Alzheimer’s Disease and Other Dementias Center, Division of Neurology, Hospital of Verona, Verona, Italy
\textsuperscript{c}Department of Clinical Pathology, S. Giovanni Hospital, Rome, Italy
\textsuperscript{d}Department of Genetics and Molecular Biology, University “La Sapienza”, Rome, Italy

Abstract. The human endothelin-converting enzyme (ECE) is involved in \(\beta\)-amyloid synthesis and regulation of the endothelin-1 (ET-1) vasoconstricting peptide. We investigated the distribution of the C-338A polymorphism of the ECE-1b gene in sporadic late-onset Alzheimer’s disease (LOAD) and in coronary artery disease (CAD) to verify its role in the onset of these two complex diseases. Two cohorts of 458 Italian Caucasian LOAD patients and 165 CAD patients were examined for the C-338A polymorphism and compared with respective control samples (260 and 106 subjects, respectively). The A allele was less present in LOAD patients than in controls, but an at limits statistically significant difference was achieved only in subjects aged less than 80 years, where only the AA genotypes appeared to have a protective role against the onset of the sporadic LOAD. For the overall CAD sample the pattern was similar and significant differences were observed only in subjects non-carrying the apolipoprotein E (APOE) \(e^4\) allele, where the A allele carrying genotypes had a protective role against the onset of the disease.

Keywords: Alzheimer’s disease, apolipoprotein E, APOE, coronary artery disease, DNA polymorphisms, endothelin-converting enzyme, ECE-1

1. Introduction

Endothelin-converting enzyme (ECE), an enzyme involved in the biosynthesis of big endothelin (ET) \[7\], generates ET-1, a potent vasoconstricting peptide with an important role in the regulation of basal vascular tone \[11\]. Two homologous proteins have been isolated: ECE-1 and ECE-2. ECE-1, being implicated in ET-1 activation, is believed to contribute to the regulation of vascular tone and cell growth in atherosclerosis \[11\]. The two proteins are encoded by different genes, ECE-1 and ECE-2, that chiefly act in endothelial and neuronal tissues, respectively \[7\]. The ECE-1 gene, the more extensively studied of the two, is located on chromosome 1, has 20 exons and four different isoforms (ECE-1a, b, c, d) generated by alternative promoters \[15\]. They have similar enzyme kinetics but dif-
ECE-1 gene variation has been recently investigated [5–7,9,10] and several variants described in particular in the promoter region. One of these variants, C-338A, is polymorphic and the A allele is reportedly associated with higher blood pressure (BP) levels in women [5,7].

Recently, a role of ECE has been hypothesized in the clearance of \( \beta \)-amyloid (A\( \beta \)), a peptide present in the abnormal plaques of the brain of Alzheimer’s disease (AD) patients. While this role has been ascertained in mice, no direct evidence in man has been found so far. In their study on C-338A polymorphism in relation to the late-onset form of AD (LOAD) in a French Caucasian population, Funalot et al. [6] found that the A Allele homozygotes had a reduced risk for the disease. This result was attributed to the increased promoter activity associated with the A allele and, consequently, with AA homozygotes.

LOAD and coronary artery disease (CAD) are both complex disorders with different pathological hallmarks, yet some convincing links between them exist. It has been reported that cardiovascular disease is associated with AD, as are the factors that cause it [14]. Studies on the association between ECE-1 gene variation and these two diseases are still quite rare. To fill this gap, we investigated C-338A polymorphism in two Italian patient samples affected with these disorders.

### 2. Materials and methods

A cohort of 458 Italian Caucasian subjects (mean age ± S.D. = 79.5 ± 7.07 years; range 62–96; men = 30.1 %, women 69.9%) affected with the sporadic late-onset (≥ 60 years) form of Alzheimer’s disease was enrolled for the study at the Division of Neurology of Verona Hospital (Northern Italy). Dementia was diagnosed according to the DSM-IV-R criteria [1]. Probable sporadic late-onset Alzheimer’s disease was diagnosed according to the NINCDS-ADRDA Work Group guidelines (revised) [12]. The control group, composed of unrelated individuals with no neurodegenerative disorders, included 260 subjects from the same area (78.9 ± 7.7; 60–99; men 41.2%, women 58.8%). The CAD group comprised 165 patients (70.7 ± 12.1; 31–98; men 69.1 %, women 30.9 %) recruited at S. Giovanni-Addolorata Hospital, Rome, who came mostly from Central and Southern Italy. The diagnosis of CAD was supported by enzyme and electrocardio-

### 3. Results

Table 1 lists the ECE-1 C-338A genotype and allele frequencies in LOAD patients and healthy subjects for the whole sample. The observed genotype frequencies fitted the ones expected according to the Hardy-Weinberg equilibrium. Across the entire sample, the A allele carrying genotypes were less frequent in patients than in controls, but the difference was not statistically significant (crude O.R. = 0.77; 95% C.I. = 0.57–1.05; \( p = 0.09 \)). Frequencies in CAD patients and respective controls are also reported in Table 1. Here too, in the overall sample, the A allele carrying genotypes in the whole sample were less frequent in patients than in
controls, but the difference was not significant (crude O.R. = 0.67; 95% CI = 0.40–1.11; p = 0.11).

Since for both these disorders other factors, such as the APOE alleles, sex and age, could influence the risk associated with the ECE-1 genotypes, the logistic regression analysis was performed and the adjusted O.R. calculated (Table 1). Inserting the interactions between the above mentioned variables and the ECE-1 genotypes revealed that in LOAD a statistically significant interaction was present between ECE-1 AA genotype and age (p = 0.024, data not shown). A statistically significant differences was observed when subjects were stratified in two age groups taking 80 years as a cut-off. This age grouping was based on the median value of the patient age distribution, and allowed us to compare very old (octogenarian) with less old subjects. More precisely, in subjects aged less than 80 years the AA genotype was significantly less frequent in patients than in controls (adjusted O.R. = 0.28; 95% C.I. 0.09–0.90; p = 0.03) (Table 2). Having stratified by age requested the Bonferroni correction for multiple comparisons to be applied. Consequently the 5% statistical significance was attained at p = 0.025 (0.05/2). This made the difference due to age significant at limits (p = 0.03).

The logistic regression analysis in CAD revealed that a statistically significant interaction was present between ECE-1 and APOE alleles (p = 0.018, data not shown). After stratification by carrying or not the APOE e*4 allele, the AA + AC genotypes were less frequent in patients with APOE non-e*4 alleles than in controls (adjusted O.R. = 0.51; 95% C.I. 0.29–0.89; p = 0.018) (Table 2). When corrected for multiple comparisons the statistical significance was attained at P = 0.025, hence the difference was yet significant.

4. Discussion

The ECE-1 human gene is involved in both β-amyloid synthesis and regulation of the ET-1 vasocon-
stricting peptide. This prompted us to investigate C-338A polymorphism in LOAD and CAD. Across the entire LOAD patient sample, the frequencies of the A allele carrying genotypes differed from those of the controls, though not significantly, confirming the trend reported by Funalot et al. [6], i.e. a lower AA genotype frequency in patients, and hence a protective effect of this genotype against the disease. After stratifying the sample by age we observed a statistically significant difference only in subjects aged less than 80 years. After correction for multiple comparisons, the AA genotype was found significantly protective though at limits, resembling what observed by Funalot et al. [6] in a sample of similar age composition. It may be supposed that with age ≥ 80 years the pathogenetic factors of AD surpass the protective effect of the ECE-1 A allele.

Also in the CAD patient sample throughout, the A allele was less frequent than in controls, resulting protective though not significantly. This finding cannot be compared with others reported in the literature for westernized populations because of lack of data. The only data that could have a connection with this topic are those of Funke-Kaiser et al. [7] and Funalot et al. [5] who both reported, though at different levels, an association of the A allele with higher blood pressure (BP), chiefly in untreated hypertensive women. Recently Wang et al. [16], in an investigation of this polymorphism in a Chinese CAD sample, reported an association of the A variant with an increased risk for the disease. The opposite trend showed by those data compared with ours could be attributed to the different genetic and environmental make up of the Chinese population with respect to the population we examined [2].

After stratifying our overall sample according with the APOE allele, a significant difference was observed in non-e*4 allele carriers, that after correction for multiple comparisons was yet statistically significant.

While in AD the finding reported in the literature that the A allele, associated with increased ECE-1 promoter activity, is protective agrees with its involvement in β-amyloid clearance, our results for CAD diverge from the data that suggested an association with BP. In this case, the protective role of the A allele contrasts with the higher BP levels reportedly associated with it. In our study we were unable to analyze the relationships between C-338A and BP levels because we had BP data only for medicated CAD patients, making them unsuitable for comparison with subjects without medication.

However, to explain why the ECE-1 A allele is protective only in the absence of the APOE e*4 allele, one needs to consider the pathogenetic mechanism of e*4 in CAD. In CAD the e*4 allele has been reportedly associated with increased levels of LDL cholesterol and total cholesterol, hence to a higher risk of cardiovascular diseases. It can be postulated that the e*4 allele diminishes the protective role of the ECE-1 A allele that can be observed when the other two APOE alleles, e*2 and e*3, are present.

In conclusion, the ECE-1 C-338A frequencies distribution in our sample of patients with sporadic LOAD confirmed the trend previously reported by Funalot et al. [6] showing a protective effect chiefly in less elderly subjects. In CAD, another complex disease in which the effect of e*4 on its onset has been variously reported [4], examined here for the first time in connection with C-338A polymorphism in a westernized population, our results indicate that the protective effect afforded by the A allele seemed to be modulated by the absence of the APOE e*4 allele.

Acknowledgments

This work was supported by the Italian National Research Council (CNR) and by 60% and 40% (Prin) grants of the Ministry for University and Scientific and Technologic Research (MURST). We wish to thank K.A. Britsch for reviewing the manuscript.

References

[1] American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington D.C., 1994.
[2] L.L. Cavalli-Sforza, P. Menozzi and A. Piazza, The History and Geography of Human Genes, Princeton. N.J. Princeton University Press, 1994.
[3] R.M. Corbo, T. Vilardo, M. Ruggeri, A.T. Gemma and R. Scacchi, Apolipoprotein E genotype and plasma levels in coronary artery disease. A case-control study in the Italian population, Clin Biochem 32 (1999), 217–222.
[4] J. Davignon, R.E. Gregg and C.F. Sing, Apolipoprotein E polymorphism and atherosclerosis, Arterioscler Thromb Vasc Biol 18 (1998), 1–21.
[5] B. Funalot, D. Courbon, T. Brousseau, O. Poirier, C. Berr, F. Cambien, P. Amouyel, J.C. Schwartz and P. Ducimetiere, Genes encoding endothelin-converting enzyme-1 and endothelin-1 interact to influence blood pressure in women: the EVA study, J Hypertens 22 (2004), 739–743.
[6] B. Funalot, T. Ouimet, A. Claperon, C. Fallet, A. Delacourte, J. Epelbaum, T. Subkowskia, N. Leonard, V. Codron, J.P. David, P. Amouyel, J.C. Schwartz and N. Helbecque, Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer’s disease, Mol Psychiatry 9 (2004), 1122–1128.
[7] H. Funke-Kaiser, F. Reichenberger, K. Kopke, S.M. Hermann, J. Pfeifer, H.D. Orzechowski, W. Zidek, M. Paul and E. Brand, Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation, *Hum Mol Genet* 12 (2003), 423–433.

[8] H. Funke-Kaiser, A. Thomas, J. Bremer, S.D. Kovacevic, K. Scheuch, I. Bolbrinker, S. Theis, J. Lemmer, A. Zimmermann, F.S. Zollmann, S.M. Herrmann, M. Paul and H.D. Orzechowski, Regulation of the major isoform of human endothelin-converting enzyme-1 by a strong housekeeping promoter modulated by polymorphic microsatellites, *J Hypertens* 21 (2003), 2111–2124.

[9] R.M. Hofstra, O. Valdenaire, E. Arch, J. O singa, H. Kroes, B.M. Loffler, A. Hamosh, C. Meijers and C.H. Buys, A loss-of-function mutation in the endothelin-converting enzyme 1 (ECE-1) associated with Hirschsprung disease, cardiac defects, and autonomic dysfunction, *Am J Hum Genet* 64 (1999), 304–308.

[10] M. Iemitsu, S. Maeda, T. Otsuki, J. Sugawara, T. Tanabe, S. Jesmin, S. Kuno, R. Ajsaka, T. Miyachi and M. Matsuda, Polymorphism in endothelin-related genes limits exercise-induced decreases in arterial stiffness in older subjects, *Hypertension* 47 (2006), 928–936.

[11] C. Ihling, T. Szombathy, B. Bohrmann, M. Brockhaus, H.E. Schaefer and B.M. Loffler, Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis, *Circulation* 104 (2001), 864–869.

[12] G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E.M. Stadlan, Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, *Neurology* 34 (1984) 939–944.

[13] S.A. Miller, D.D. Dykes and H.F. Polesky, A simple salting out procedure for extracting DNA from human nucleated cells, *Nucleic Acids Res* 16 (1988), 1215.

[14] M.J. Stampfer, Cardiovascular disease and Alzheimer’s disease: common links, *J Intern Med* 260 (2006), 211–223.

[15] O. Valdenaire, E. Rohrbacher and M.G. Mattei, Organization of the gene encoding the human endothelin-converting enzyme (ECE-1), *J Biol Chem* 270 (1995), 29794–29798.

[16] L.-S. Wang, N.-P. Tang, H.-J. Zhu, B. Zhou, L. Yang and B. Wang, Endothelin-converting enzyme-1b C-338A polymorphism is associated with the increased risk of coronary artery disease in Chinese population, *Clin Chim Acta* 384 (2007), 75–79.

[17] P.R. Wenham, W.H. Price and G. Blandell, Apolipoprotein E genotyping by one-stage PCR, *Lancer* 337 (1991), 1158–1159.